MedPath

UI researchers receive funding for clinical trials in new cancer treatment - The Daily Iowan

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Potential Breakthrough in Dual Cellular Therapy for Advanced and Metastatic Solid Tumors

Roswell Park Comprehensive Cancer Center is conducting a phase 1 clinical trial, OASIS, to evaluate the effectiveness of a genetically modified oncolytic virus, CF33-CD19, combined with blinatumomab, in treating advanced or metastatic solid tumors. This innovative approach aims to extend the benefits of cellular immunotherapies to patients with cancers resistant to traditional therapies.

OSF Healthcare and Kevin Brown Strong Foundation Partner to Advance Glioblastoma Clinical Trials

OSF Healthcare Cancer Institute is conducting a clinical trial to enhance oxygen delivery to glioblastoma tumors, improving treatment effectiveness.
The Kevin Brown Strong Foundation donated $250,000 to OSF to expand access to glioblastoma clinical trials in central Illinois.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.
A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months.

Radiopharmaceutical Developed by PhD Student to Enhance Lung Cancer Immunotherapy Delivery to Brain Metastases

A novel radiopharmaceutical developed by Stephanie Borlase will be used in a clinical trial to track immunotherapy delivery to brain metastases in lung cancer patients.
The trial aims to assess whether ultrasound can disrupt the blood-brain barrier, enhancing the uptake of immunotherapy drugs in brain tumors.

Injectable Oxygen Microbubbles Show Promise in Treating Hypoxemia and Preventing Organ Damage

Researchers have developed injectable oxygen microbubbles for rapid oxygen delivery during critical moments of cardiac or respiratory arrest, addressing the limitations of traditional methods.
In preclinical testing, pH-sensitive microbubbles delivered precise amounts of oxygen, significantly improving survival and preventing catastrophic organ damage in hypoxemic conditions.

Implantable Microparticles Deliver Dual Cancer Therapy, Eradicating Tumors in Mice

Researchers have developed implantable microparticles that deliver both heat and chemotherapy directly to tumor sites, enhancing treatment efficacy.
In a mouse model of triple-negative breast cancer, the dual therapy eradicated tumors and significantly prolonged survival compared to single therapies.

Inimmune's INI-4001 Advances to Human Cancer Trials in Australia

Inimmune Corporation's INI-4001, a novel cancer treatment compound developed in collaboration with the University of Montana, is moving into human clinical trials in Australia.
The decision to conduct initial trials in Australia was influenced by faster trial initiation processes compared to the United States, with plans to expand to U.S. trials later.

Strategic Collaborations and Novel Therapies Advance Cancer and Brain Injury Treatment

AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors.
SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials.

University of Montana's Cancer Immunotherapy Enters Phase 1 Human Trials

Researchers at the University of Montana, in partnership with Inimmune, have advanced a novel cancer treatment into Phase 1 human clinical trials.
The immunotherapy drug, initially developed as an influenza vaccine, aims to retrain the body's immune system to target and destroy cancerous cells.

Oleolive Receives NCI Grant to Study Propentofylline for Glioblastoma Treatment

Oleolive, Inc. has been awarded a $400,000 STTR grant from the National Cancer Institute to investigate propentofylline's potential in glioblastoma treatment.
Propentofylline, a repurposed drug, will be studied for its ability to enhance the chemosensitivity of glioblastoma tumor cells, potentially improving patient outcomes.

Reference News

[1]
UI researchers receive funding for clinical trials in new cancer treatment - The Daily Iowan
dailyiowan.com · Nov 22, 2024

James Byrne at the University of Iowa uses foam science to develop gas-entrapping materials for cancer treatment, aiming...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy